Hi all. After a long break from this board, I wanted to pose a two part question regarding our NASH trial. I see that Inventiva Pharm has recently begun a lengthy phase 3 trial for NASH and I believe that they received BTD for NASH in 2019. Question 1 - do we consider their drug Lanifibranor to be a true competitor to Leronlimab for NASH; Question 2 - why doesn't Inventiva's market cap reflect anything near the $8 billion market cap that I thought is supposed to come along with a BTD? For the record, I am still long and strong Cytodyn, and I have never sold a share of my investment! Thanks.